BIOCARDIA INC BCDA
COM · Common Stock · CUSIP 09060U507
- SectorHealth care
- IndustryBiological Products, (No Diagnostic Substances)
- HeadquartersSunnyvale, CA
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.34.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 24 |
| Q4 2022 | 26 |
| Q1 2023 | 24 |
| Q2 2023 | 24 |
| Q3 2023 | 17 |
| Q4 2023 | 25 |
| Q1 2024 | 23 |
| Q2 2024 | 1 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 10 | 7 |
| Q1 2023 | 5 | 10 |
| Q2 2023 | 12 | 9 |
| Q3 2023 | 2 | 13 |
| Q4 2023 | 14 | 1 |
| Q1 2024 | 9 | 9 |
| Q2 2024 | 0 | 23 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2023 | $112.6k | $3.0k | 0.03 |
| Q4 2023 | $137.2k | $664 | 0.00 |
| Q1 2024 | $7.0k | $0 | 0.00 |
| Q2 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| CM Management, LLC | Sold out | -700.0k |
| VANGUARD GROUP INC | Sold out | -650.8k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -155.9k |
| TWO SIGMA SECURITIES, LLC | Sold out | -111.1k |
| Family Manage LLC | Sold out | -77.5k |
| BlackRock Inc. | Sold out | -45.9k |
| BROWN ADVISORY INC | Sold out | -33.1k |
| COMMONWEALTH EQUITY SERVICES, LLC | Sold out | -30.0k |
| STATE STREET CORP | Sold out | -21.0k |
| NORTHERN TRUST CORP | Sold out | -19.2k |
Insider purchases and sales in Q2 2024
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2022 | 1 | $13.5k | 0 | — | — |
| Q4 2022 | 2 | $12.5k | 0 | — | — |
| Q1 2023 | 0 | — | 0 | — | — |
| Q2 2023 | 1 | $9.9k | 0 | — | — |
| Q3 2023 | 1 | $7.4k | 0 | — | — |
| Q4 2023 | 0 | — | 0 | — | — |
| Q1 2024 | 1 | — | 0 | — | — |
| Q2 2024 | 1 | $7.4k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2024-06-28 | Altman Peter President and CEO, director | Bought | $598200 shares |
| 2024-06-21 | Altman Peter President and CEO, director | Bought | $1.6k500 shares |
| 2024-06-14 | Altman Peter President and CEO, director | Bought | $1.8k500 shares |
| 2024-06-10 | Altman Peter President and CEO, director | Bought | $3.4k1.0k shares |
| 2024-04-19 | Altman Peter President and CEO, director | Bought | —2.8k shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2024
| Manager | Shares | Change |
|---|---|---|
| OSAIC HOLDINGS, INC. 0.00% of their portfolio | 11.2k $3.8k | Reduced -10.2k |